European Medicines Agency recommends a variation to the terms of the marketing authorisation for panitumumab

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product panitumumab (Vectibix). Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer. Read more here.